Key takeaways

  • LSIL is NOT cancer and is not the same as a high-grade (precancerous) lesion — it reflects mild cell changes from an active HPV infection.
  • About 60–90% of LSIL cases regress to normal on their own within 1–2 years as the immune system clears HPV, with the highest clearance in younger women.
  • Most LSIL needs follow-up (a repeat test or colposcopy), not immediate surgery — risk-based triage avoids over-treatment.
  • Progression to a high-grade lesion is uncommon, and the journey from HPV infection to cervical cancer typically takes 10–20 years, which is why screening works so well.
  • HPV vaccination (including Cervavac, Gardasil 4 and Gardasil 9 in India) plus regular screening is the most effective way to prevent cervical cancer.
  • Quitting tobacco, attending follow-up appointments and keeping up with screening protect your long-term cervical health.

What LSIL means on your Pap report

LSIL stands for low-grade squamous intraepithelial lesion — a term from the Bethesda System, the standard way Pap smear (cytology) results are reported worldwide, including in India. It describes mild changes in the squamous cells lining your cervix, usually the footprint of a recent or ongoing HPV infection.

The Bethesda System sorts squamous cell findings along a spectrum, from completely normal to cancer:

  • NILM (Negative for Intraepithelial Lesion or Malignancy): a normal result.
  • ASC-US (Atypical Squamous Cells of Undetermined Significance): borderline changes that may or may not be meaningful.
  • LSIL: mild changes consistent with active HPV infection or mild dysplasia (CIN 1).
  • ASC-H: borderline changes that cannot rule out a high-grade lesion.
  • HSIL (High-grade Squamous Intraepithelial Lesion): more concerning changes (moderate to severe dysplasia, CIN 2/CIN 3).
  • Squamous Cell Carcinoma: cancer cells are present.

It helps to understand one key distinction. LSIL is a cytology term (what cells look like on a Pap smear), while CIN 1 is a histology term (what tissue looks like under the microscope after a biopsy). LSIL on a Pap suggests CIN 1, but only a biopsy can confirm it. Under the microscope, LSIL typically shows koilocytosis (a halo around the nucleus — the classic sign of HPV), mild nuclear enlargement, and darker-staining nuclei.

### HPV: the cause behind LSIL

Human papillomavirus underlies virtually all cervical cell changes. Of the 200-plus HPV types, about 14 are "high-risk" because they can cause cancer — most importantly HPV 16 and 18, which account for roughly 70% of cervical cancers. Low-risk types (such as HPV 6 and 11) tend to cause genital warts rather than cancer. You can read more in our overview of HPV types, symptoms and treatment. LSIL is usually caused by a transient HPV infection — high-risk or low-risk — that the immune system can clear over months to years.

### Why LSIL so often goes away

A healthy immune system frequently clears HPV on its own, especially in younger women. As the infection resolves, the cell changes regress and later Pap smears return to normal. Roughly 60–90% of LSIL cases regress within 1–2 years. When LSIL does progress, the pathway is gradual — HPV infection → mild changes (LSIL/CIN 1) → if HPV persists, moderate then severe dysplasia (HSIL) → invasive cancer — and the full journey usually takes 10–20 years. That slow timeline is exactly why screening is so effective: changes can be caught and treated long before cancer develops.

### How common is it?

LSIL is one of the most frequently reported abnormal Pap results — roughly 2–5% of all Pap smears, higher in women under 30 (around 4–8%) and lower after 50. It is substantially more common in women who are immunocompromised, such as those living with HIV.

### The India context

Cervical cancer is the second most common cancer in Indian women after breast cancer, with around 1,24,000 new cases and 77,000 deaths a year (GLOBOCAN estimates) — yet it is largely preventable through vaccination and screening. Screening coverage in India remains limited, and ICMR and state programmes are working to expand it. Catching LSIL during screening is the early step that allows cervical cancer to be prevented through simple follow-up.

### What LSIL is NOT

LSIL is not cancer, not a high-grade precancer, and not a final diagnosis. Framing it as a "precancer" that demands urgent, aggressive treatment is inaccurate and causes needless anxiety. The honest framing: LSIL reflects an active HPV infection with mild cell changes that usually clear within 1–2 years, needs sensible follow-up to catch the minority that persist, and is a cue to focus on prevention. For the bigger picture of how cervical cells change and recover, see our guide to cervical changes and what to do after an abnormal Pap smear.

Natural history: regression, persistence and progression

Understanding what usually happens after an LSIL result explains why doctors watch and re-test most cases rather than rushing to treat them.

Regression (the most common outcome). Roughly 60–90% of LSIL cases return to normal within 1–2 years. Regression is highest in younger women (often over 90% in those under 21, 70–80% in the 20s) and somewhat lower with age. As the immune system clears HPV — through T cells, natural killer cells and antibodies — the cell changes the virus caused simply fade.

Persistence. About 10–30% of LSIL cases are still present at 1–2 year follow-up. Importantly, persistent LSIL is still LSIL, not a high-grade lesion. It warrants continued monitoring but usually not treatment.

Progression. Progression to a high-grade lesion (CIN 2/3) happens in roughly 5–20% over two years; progression to invasive cancer over that period is under 1%. Progression is more likely with:

  • A persistent high-risk HPV infection, especially HPV 16 or 18
  • Older age (less immune clearance)
  • A weakened immune system (HIV, transplant, immunosuppressive medication)
  • Ongoing tobacco use
  • Repeated abnormal screening over time

Why this shapes management. Because most LSIL regresses, treating every case immediately with a procedure like LEEP would over-treat the majority who never needed it. Over-treatment carries real downsides — bleeding, infection, cervical narrowing (stenosis), a modestly higher risk of preterm birth in future pregnancies, plus cost and anxiety. Risk-based management aims to find and treat the few cases that need it while sparing the many that don't.

When treatment does become appropriate includes a biopsy confirming CIN 2/3, LSIL that persists despite proper observation (usually around two years), or factors that raise progression risk such as HIV. After colposcopy and biopsy, follow-up is tailored to the result: CIN 1 (or normal) is typically watched with repeat Pap and HPV testing at around 12 months; CIN 2 depends on age and fertility plans; CIN 3 is usually treated. For more on these tissue grades, see our explainer on cervical dysplasia.

Many Indian women receiving an LSIL result feel disproportionate fear of cancer and face pressure for immediate treatment from clinicians less familiar with risk-based care. Accurate information about LSIL's favourable natural history supports calmer, better decisions — and care at a centre that follows current guidelines.

Your next steps: management by age and HPV status

Management of LSIL is decided by your age, your HPV co-test result and your screening history, following the widely used ASCCP 2019 risk-based guidelines (aligned with FOGSI and ICMR guidance in India). The principle is simple: estimate the risk of a high-grade lesion and match the intensity of care to that risk — anywhere from continued surveillance to colposcopy to treatment.

Age 25+ with LSIL and a positive HPV co-test. Colposcopy with biopsy is usually recommended, because the risk is high enough to look directly at the cervix. If the biopsy shows CIN 1 or normal, you move to surveillance.

Age 25+ with LSIL and a negative HPV co-test. The risk is lower. Options include colposcopy or simply repeating the co-test at 12 months, depending on your preference and local resources. Many providers still recommend colposcopy as the thorough option.

Age 25+ with LSIL and unknown HPV status. Colposcopy is generally advised, with HPV testing done around the same time to refine the plan.

Age 21–24 (where screened). Because regression rates are very high at this age, a repeat Pap at 12 months is acceptable, with colposcopy deferred unless abnormalities persist. In India, screening usually starts at 25–30, so this group is less commonly relevant here.

Pregnancy. Colposcopy is safe and can be done at any stage, but endocervical curettage (sampling inside the cervical canal) is avoided to prevent trauma. Treatment of high-grade lesions is generally postponed until after delivery unless cancer is suspected. Pregnancy does not meaningfully change LSIL's natural history.

After menopause. Colposcopy is generally recommended. Thinning (atrophic) changes after menopause can mimic LSIL, so careful evaluation — and an HPV co-test — helps distinguish the two.

If you are immunocompromised. Women living with HIV, transplant recipients and others on immunosuppression are managed more actively: colposcopy with biopsy, a lower threshold to treat, and closer surveillance, alongside optimising overall immune health. Antiretroviral therapy with a controlled viral load improves outcomes but does not remove the need for vigilant screening.

### Why the HPV co-test matters so much

HPV co-testing sharpens risk prediction. HPV-negative LSIL has a very favourable outlook, while HPV-positive LSIL — particularly HPV 16 or 18 — carries higher risk and warrants closer attention. HPV genotyping (which specifically identifies 16 and 18) adds further detail.

Access in India. HPV co-testing is available at private labs such as Dr Lal PathLabs, SRL, Metropolis and Thyrocare, typically ₹2,500–5,000, and is free or subsidised through some state screening programmes (this varies by state). Many private gynaecology packages now include it. For more on the test itself, see cervical cancer screening.

Major private and government centres — including Tata Memorial (Mumbai), AIIMS (Delhi), PGIMER (Chandigarh), Cancer Institute Adyar (Chennai) and Kidwai (Bengaluru) — provide ASCCP-aligned management. Care in smaller towns can be less consistent, so a centre familiar with current guidelines is worth seeking out. Ultimately, LSIL decisions are shared decisions, weighing your age, HPV status, biopsy results, fertility plans, access and cost. For prevention, see our guide to the HPV vaccine in India (Cervavac and Gardasil).

Colposcopy and biopsy: the Indian pathway

Colposcopy is the test that shows whether your LSIL cytology corresponds to a real lesion on the cervix, and it guides what (if anything) needs treating.

What it is. A colposcope is a lighted magnifying instrument (5–40x) used to look closely at the cervix. After a speculum is placed (much like a Pap smear), the doctor applies dilute acetic acid — ordinary vinegar — which turns abnormal areas white, and sometimes Lugol's iodine, which stains healthy tissue brown while abnormal areas stay pale. Any suspicious area is then biopsied with small forceps. The whole appointment usually takes 15–30 minutes. It can feel like a Pap smear with some extra pinching if a biopsy is taken, but it is not usually painful and rarely needs anaesthesia. Our detailed walkthrough of the colposcopy procedure and cost in India covers what to expect.

How to prepare. Avoid intercourse, tampons and douching for 24–48 hours beforehand, and ideally schedule it when you are not menstruating for clearer views — though it can be done around your period if needed. Bring the Pap report that prompted the referral.

Aftercare. Light spotting for a few days is normal — use a pad, not a tampon. Mild cramps respond to paracetamol or ibuprofen. If Monsel's solution was used to stop bleeding, expect brown or black discharge for several days. Avoid intercourse, tampons and douching for 1–2 weeks while the biopsy site heals.

When to call your doctor: heavy bleeding (soaking a pad in an hour), severe pain, fever, or foul-smelling discharge.

Reading the biopsy. Results usually take 1–2 weeks. Possible outcomes are normal, CIN 1 (confirms low-grade changes), CIN 2 (moderate), CIN 3 (severe / carcinoma in situ), or — very rarely from an LSIL Pap — invasive cancer. The biopsy plus your cytology then determines the plan. Sometimes cytology and biopsy disagree; a repeat colposcopy or a small diagnostic excision may be considered.

If the view is inadequate. Colposcopy is "inadequate" when the transformation zone isn't fully visible — more likely with age, after menopause, or after previous cervical procedures. Options then include endocervical curettage, a short course of vaginal estrogen to improve visibility in postmenopausal women, or a diagnostic excision for a larger tissue sample.

Availability and cost in India. Private hospitals (Apollo, Cloudnine, Manipal, Fortis and others) typically charge ₹3,000–8,000 for colposcopy, plus ₹1,500–3,000 for biopsy and pathology — roughly ₹5,000–12,000 in total. Government cancer centres (Tata Memorial, AIIMS, PGIMER, JIPMER, Cancer Institute Adyar, Kidwai, RCC Trivandrum, Chittaranjan National Cancer Institute Kolkata, MNJ Hyderabad) offer it at little or no cost, though waits can be longer. State screening programmes in Tamil Nadu, Kerala, Maharashtra and Punjab are extending colposcopy through public networks. Most major health insurance plans cover diagnostic procedures with the right referral. Keep a written record of your screening history and confirm a follow-up appointment for your results.

Treatment when it's needed: LEEP and alternatives

Most LSIL with a CIN 1 biopsy needs no treatment, because it usually regresses on its own. Treatment is reserved for confirmed high-grade lesions (CIN 2/3) and, in selected cases, persistent disease.

When treatment is indicated: confirmed CIN 2 (often treated in older women; sometimes observed in younger women planning pregnancy), confirmed CIN 3, persistent CIN 1 after about two years of observation, or persistent HPV 16/18-related LSIL despite surveillance — always with your informed consent after counselling.

### The procedures

Excisional procedures remove the abnormal tissue (and can be examined by pathology):

  • LEEP (Loop Electrosurgical Excision Procedure) — the most common option. A fine electrified wire loop removes part of the cervix, including the transformation zone, usually in an outpatient setting under local anaesthesia in 15–30 minutes.
  • Cold-knife conization — surgical removal of a cone of cervix in an operating theatre under regional or general anaesthesia, used when a larger or glandular specimen is needed.
  • Laser conization — similar, less common in India.

Ablative procedures destroy abnormal tissue without removing it (so there is no specimen for pathology):
  • Cryotherapy — freezing small, well-seen lesions.
  • Thermal ablation (cold coagulation) — increasingly used in Indian programmes for selected CIN 2/3.

The lack of a tissue specimen is the main drawback of ablation — if hidden invasive cancer were present, it could be missed — so excision is preferred when there is any doubt. Read our dedicated guide to LEEP in India for the full procedure and recovery.

### LEEP recovery and risks

Expect watery, brownish discharge and light bleeding for 1–3 weeks and cramping for a day or so; avoid intercourse and tampons for 4–6 weeks, with a check-up at 4–6 weeks. LEEP is generally safe. Possible complications include bleeding, infection, cervical stenosis (which can affect periods or future IUD insertion), and a modestly increased risk of preterm birth in later pregnancies — roughly 1.5–2 times higher, more so with larger excisions. Recurrence occurs in about 5–15% over two years, which is why follow-up matters.

Fertility. Most women conceive and carry pregnancies normally after LEEP. Because of the small rise in preterm-birth and cervical-insufficiency risk, fertility plans are worth discussing beforehand — and for CIN 2 in younger women, careful observation rather than immediate treatment may be appropriate, with treatment reserved for progression. Cervical length monitoring in a future pregnancy can identify the rare case needing a cervical cerclage.

### After treatment

Follow-up is essential: a Pap with HPV co-test at 6 and 12 months, then yearly for several years, with colposcopy if anything is abnormal, and long-term surveillance for at least 5–10 years per guidelines.

Costs in India. LEEP is roughly ₹8,000–15,000 at private hospitals and free or nominal at government cancer centres, where it is increasingly offered through state screening programmes. Alongside treatment, keep up with prevention — see four key ways to prevent HPV.

Prevention: HPV vaccination and screening

HPV vaccination and regular screening together are the most effective way to prevent cervical cancer. One stops the infection that causes it; the other catches changes early if they do occur.

### HPV vaccination

Vaccines protect against the HPV types behind roughly 70–90% of cervical cancers, depending on the vaccine. In India you can choose from:

  • Cervavac (Serum Institute of India) — a quadrivalent vaccine against HPV 6, 11, 16 and 18, launched in 2023 at a substantially lower price (about ₹2,000–4,000 for the course) and increasingly available at pharmacies and clinics.
  • Gardasil 4 — quadrivalent (HPV 6, 11, 16, 18), about ₹3,000–4,000 per dose.
  • Gardasil 9 — nine-valent, adding protection against HPV 31, 33, 45, 52 and 58, about ₹4,500–6,500 per dose.

Who and when. The ideal time is before sexual debut (ages 9–14, two doses 6–12 months apart). Catch-up runs through 26 (three doses), with shared-decision catch-up up to 45, especially with risk factors or new partners. Crucially, vaccination still helps women who are already sexually active or who already have LSIL — it protects against HPV types you haven't yet acquired and may lower the risk of recurrence after treatment. Our full guide covers the HPV vaccine in India.

The programme. Vaccination is largely private and self-paid for now, though a phased national rollout is planned, and states such as Sikkim, Punjab and Delhi have begun adolescent programmes. Vaccinating sons too reduces genital warts, certain cancers and overall transmission.

### Cervical cancer screening

Screening finds and treats precancerous changes before cancer develops. Options include the Pap smear (cytology), the HPV test, the HPV–Pap co-test (most sensitive), and visual inspection with acetic acid (VIA) in lower-resource settings. ICMR and Indian guidelines generally recommend:
  • Start screening at age 25–30
  • Pap every 3 years, or HPV test every 5 years, or co-test every 5 years
  • Continue to 65 if prior screening has been adequate and normal
  • Earlier, more frequent screening for higher-risk groups (such as women living with HIV)

If you've never been screened, our guide to your first Pap smear walks you through it. Access: state programmes in Tamil Nadu, Kerala, Maharashtra, Punjab and elsewhere offer free screening; private costs are roughly ₹500–2,000 for a Pap, ₹2,500–5,000 for HPV testing, and ₹3,000–6,000 for a co-test.

### Beyond vaccines and tests

Quitting tobacco supports HPV clearance and lowers progression risk. Condoms give partial protection against HPV (it can affect skin they don't cover), and a healthy immune system helps your body clear the virus. For women living with HIV, antiretroviral therapy plus earlier, more frequent screening is key. Investing in these prevention steps for yourself and your family is one of the highest-value health decisions available.

Special situations: pregnancy, menopause and immunocompromise

Some groups have particular considerations, though the calm, follow-up-focused approach to LSIL stays the same.

Pregnancy. Pregnancy doesn't meaningfully change LSIL's natural history. Continue routine screening, and manage abnormal results much as you would otherwise — colposcopy is safe at any stage (often scheduled in the second trimester), and biopsy of suspicious lesions is fine if needed. Endocervical curettage is avoided in pregnancy, and treatment of confirmed high-grade lesions is generally deferred to about 6–8 weeks postpartum unless cancer is suspected. Routine LSIL often simply warrants postpartum reassessment.

After menopause. Estrogen-deficient (atrophic) changes can mimic LSIL on cytology. A few weeks of vaginal estrogen before a repeat Pap can clarify the picture, and an HPV co-test helps stratify risk — HPV-negative atrophic changes are reassuring, while HPV-positive abnormal cytology warrants colposcopy regardless. Because the transformation zone often sits higher with age, colposcopy may be inadequate and need endocervical sampling or an estrogen course first.

If you are immunocompromised. Women living with HIV, transplant recipients and those on immunosuppressive therapy have a higher risk of cervical disease and are managed more actively — earlier, more frequent (often annual) screening, a lower threshold for colposcopy, more readiness to treat, and closer surveillance afterwards. NACO and FOGSI guidance recommends annual screening and colposcopy for any abnormality in women with HIV, with free or low-cost care through NACO programmes.

After previous abnormal or treated results. History of LSIL or treated lesions calls for ongoing, closer surveillance — typically annual Pap and HPV co-testing for at least 5–10 years — because new HPV infections and recurrence (5–15%) can occur.

Sex and relationships. An LSIL result does not require abstinence; you can continue normal sexual activity. Partner notification isn't required for LSIL (unlike some STIs), though sharing your HPV history is your choice. Condoms offer partial protection.

Your mental health. Even with a favourable outlook, an abnormal cervical result can be distressing. Accurate information, a clear follow-up plan and support from people you trust all help. If anxiety becomes significant, counselling (in person or via Indian platforms such as YourDOST, MindPeers or Wysa, often ₹500–2,000 a session) is worth seeking.

The bottom line. Most LSIL regresses, even persistent or progressed disease can be treated effectively, and cervical cancer is preventable with proper follow-up. LSIL is the start of a manageable relationship with your cervical health — not a crisis.

When to see a doctor

An LSIL result itself is not an emergency, but it should always be followed up — and certain symptoms deserve prompt attention regardless of your Pap result.

Book an appointment to discuss your LSIL report and arrange the recommended follow-up (repeat testing or colposcopy). Don't ignore the letter, and don't assume it means cancer.

See a doctor sooner if you notice any of these:

  • Bleeding between periods, after sex, or after menopause
  • Unusual or foul-smelling vaginal discharge
  • Pelvic or lower-abdominal pain that is new or persistent
  • Pain during sex

After a colposcopy, biopsy or LEEP, seek care for heavy bleeding (soaking a pad within an hour), fever, severe pain, or foul-smelling discharge — these can signal infection or excessive bleeding.

If you are living with HIV or are otherwise immunocompromised, or if you have missed screening for several years, ask your provider about a more tailored follow-up schedule.

LSIL myths in India, corrected

Myth: LSIL means I have cervical cancer or will get it soon

  • False. LSIL is not cancer and not a high-grade precancer. It reflects mild cell changes from an active HPV infection, and 60–90% of cases regress to normal within 1–2 years as the immune system clears the virus.
  • Progression to a high-grade lesion (CIN 2/3) over two years is uncommon (about 5–20%), and progression to invasive cancer over that time is rare (under 1%). The pathway from HPV infection to cancer usually takes 10–20 years — which is exactly why screening and follow-up are so effective. See cervical changes for the bigger picture.

Myth: LSIL requires immediate LEEP or cervical surgery

  • False. Most LSIL needs no immediate treatment. Risk-based management (ASCCP, widely used in India) recommends colposcopy with biopsy when indicated, surveillance with repeat Pap and HPV testing for biopsy-confirmed CIN 1, and LEEP reserved mainly for confirmed CIN 2 or CIN 3.
  • Treating every LSIL immediately would over-treat the majority who would have regressed, exposing them to bleeding, infection, cervical narrowing and a modestly higher preterm-birth risk in later pregnancies. Risk-based care balances these. Read four key ways to prevent HPV.

Myth: HPV vaccination is only for young girls and pointless if you already have LSIL

  • False on both counts. Sexually active women still benefit, because the vaccine protects against HPV types they haven't yet acquired, and women with current LSIL or treated lesions may see a lower risk of recurrence.
  • India's options include Cervavac (about ₹2,000–4,000 per course), Gardasil 4 (₹3,000–4,000 per dose) and Gardasil 9 (₹4,500–6,500 per dose), with catch-up commonly recommended through 26 and shared-decision catch-up to 45. Vaccination plus screening protects far more than either alone — see the HPV vaccine in India.

Myth: If LSIL goes away, I don't need screening anymore

  • False. HPV infections and cell changes can recur, and a history of LSIL is a reason to keep screening. After LSIL clears, return to routine intervals (Pap every 3 years, or HPV/co-test every 5 years) through the screening age range, with closer surveillance after treated high-grade lesions.
  • An LSIL result starts an ongoing relationship with your cervical health, not a one-time event. India's state programmes (free) and private testing (₹500–5,000) make lifelong screening accessible. If you've never been screened, start with your first Pap smear.

Frequently asked questions

Is LSIL the same as cervical cancer?

No. LSIL means mild cell changes on your cervix, almost always from a common HPV infection. It is not cancer and not a high-grade precancer. Most cases (60–90%) clear on their own within 1–2 years, and progression to cancer is rare and slow — which is why follow-up, not panic, is the right response.

Will my LSIL go away on its own?

Most likely, yes. Around 60–90% of LSIL cases regress to normal within 1–2 years as the immune system clears HPV, with the highest clearance in younger women. That's why doctors often recommend repeat testing or surveillance rather than immediate treatment.

What is the next step after an LSIL Pap result in India?

It depends on your age and HPV status. For women 25 and older — especially if the HPV co-test is positive — colposcopy with biopsy is usually recommended. If HPV is negative, repeating the co-test in 12 months may be an option. A biopsy showing CIN 1 is generally watched, not treated.

Does LSIL affect my ability to get pregnant?

LSIL by itself does not affect fertility or pregnancy. Even if treatment like LEEP becomes necessary, most women conceive and carry pregnancies normally — there is a small increase in preterm-birth risk, which is why fertility plans are discussed before any procedure.

How much does follow-up for LSIL cost in India?

It varies. HPV co-testing runs roughly ₹2,500–5,000 at private labs, colposcopy with biopsy around ₹5,000–12,000 privately, and LEEP about ₹8,000–15,000. Government cancer centres and several state screening programmes offer these at little or no cost, though waits can be longer.

Can I still get the HPV vaccine if I already have LSIL?

Yes. Vaccination still protects against HPV types you haven't yet acquired and may reduce the risk of recurrence. Catch-up vaccination is commonly recommended through age 26, with shared-decision catch-up up to 45. Discuss timing with your doctor.

Sources